Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
- PMID: 30643555
- PMCID: PMC6322585
- DOI: 10.2217/lmt-2016-0016
Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
Keywords: cost–effectiveness; health technology assessment; immunotherapy; lung cancer.
Conflict of interest statement
Financial & competing interests disclosure P Aguiar Jr has received honoraria from BMS and AstraZeneca. He has received research honoraria from Roche and is speaker for MSD and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
References
-
- IARC: fact sheets by population. 2016. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
-
- American Cancer Society: the global economic cost of cancer. 2010. http://www.cancer.org/acs/groups/content/@internationalaffairs/documents...
-
- Tribunal de Contas da União: Política Nacional de Atenção Oncológica132. 2011. http://portal.tcu.gov.br/lumis/portal/file/fileDownload.jsp?inline=1&fil...
-
- Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J. Clin. 2008;58(1):9–31. - PubMed
Publication types
LinkOut - more resources
Research Materials